Immunoâ€Oncology Versus Precision Medicine: Where Is Cancer Care Headed?
At the 5th annual Patient-Centered Oncology Care® meeting, hosted by The American Journal of Managed Care®, experts discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.
Pharma—PBM War on Drug Prices Picks Up Steam
An e-mail, from Mark Merritt, president and CEO of the trade group Pharmaceutical Care Management Association, to the organization’s board, lays out a plan to develop an aggressive campaign to convince the new administration that the fault rests with pharmaceutical manufacturers.
Michigan Study Finds Obesity Lowers Hospice Use Among Seniors
A long-term health study has found that seniors with a higher body mass index were less likely to make use of hospice care. Additionally, obese seniors spent significantly fewer days in hospice care than their nonobese counterparts.
Senator Cassidy Presents Competing Options to Replace the ACA
At the AcademyHealth National Health Policy Conference in Washington DC, Senator Bill Cassidy spoke about the potential replacement of the Affordable Care Act and the options that the Republican administration is considering for the replacement.
First Trial With Universal CAR-T Treatment in Pediatric Leukemia Reports Success
“Off-the-shelf” chimeric antigen receptor (CAR)-T cells, also known as universal donor cells, were used in 2 young infants with relapsed, refractory acute lymphoblastic leukemia resulted in molecular remission in 28 days in both infants.
Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML
At the 58th annual meeting of the 58th American Society of Hematology, representatives from 2 national clinical trials, Beat AML and NCI-MATCH, detailed how they were incorporating genomic profiling to assign patients to different treatment arms.
Healthcare Utilization and Costs Associated With the Treatment of Relapsed/Refractory MM
A poster presented at the 58th Annual Meeting & Exposition of the American Society of Hematology compared the utilization patterns and associated costs for recently approved and older drugs in patients with relapsed/refractory multiple myeloma in the United States.